UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

At November 5, 2012, 7,362,573,528 shares of the issuer s voting common stock were outstanding.

Table of Contents

FORM 10-Q

For the Quarterly Period Ended

September 30, 2012

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2012 and October 2, 2011

Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2012 and October 2, 2011

Condensed Consolidated Balance Sheets as of September 30, 2012 and December 31, 2011

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2012 and October 2, 2011

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

50

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

51

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

95

Item 4.

Controls and Procedures

95

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

96

Item 1A.

Risk Factors

96

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

97

Item 3.

Defaults Upon Senior Securities

97

Item 4.

Mine Safety Disclosures

97

Item 5.

Other Information

97

Item 6.

Exhibits

98

Signature

99

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

September 30,

2012

October 2,

2011

September 30,

2012

October 2,

2011

Revenues

13,976

16,609

43,918

49,118

Costs and expenses:

Cost of sales(a)

2,665

3,409

8,162

10,449

Selling, informational and administrative expenses(a)

3,847

4,457

11,801

13,635

Research and development expenses(a)

1,981

2,176

5,734

6,487

Amortization of intangible assets

1,228

1,389

3,939

4,138

Restructuring charges and certain acquisition-related costs

302

1,090

1,089

2,458

Other deductions net

962

547

3,283

1,802

Income from continuing operations before provision for taxes on income

2,991

3,541

9,910

10,149

Provision/(benefit) for taxes on income

(119

1,216

1,882

3,167

Income from continuing operations

3,110

2,325

8,028

6,982

Discontinued operations:

Income from discontinued operations net of tax

104

96

249

303

Gain on sale of discontinued operations net of tax

1,328

1,316

Discontinued operations net of tax

104

1,424

249

1,619

Net income before allocation to noncontrolling interests

3,214

3,749

8,277

8,601

Less: Net income attributable to noncontrolling interests

11

22

31

Net income attributable to Pfizer Inc.

3,208

3,738

8,255

8,570

Earnings per common share basic:(b)

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.42

0.30

1.07

0.88

Discontinued operations net of tax

0.01

0.18

0.03

0.21

Net income attributable to Pfizer Inc. common shareholders

0.43

0.48

1.10

1.09

Earnings per common share diluted:(b)

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.41

0.30

1.06

0.88

Discontinued operations net of tax

0.01

0.18

0.03

0.20

Net income attributable to Pfizer Inc. common shareholders

0.43

0.48

1.09

1.08

Weighted-average shares Basic

7,436

7,770

7,483

7,877

Weighted-average shares Diluted

7,508

7,810

7,550

7,925

Cash dividends paid per common share

0.22

0.20

0.66

0.60

(a)

Exclusive of amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.

(b)

EPS amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS OF DOLLARS)

September 30,

2012

October 2,

2011

September 30,

2012

October 2,

2011

Net income before allocation to noncontrolling interests

3,214

3,749

8,277

8,601

Other Comprehensive Income/(Loss)

Foreign currency translation adjustments

153

(1,565

2,546

Reclassification adjustments(a)

(130

(137

153

(130

(1,565

2,409

Unrealized holding gains/(losses) on derivative financial instruments

446

(1,051

217

(516

Reclassification adjustments for realized (gains)/losses(a)

(221

653

(95

(81

225

(398

122

(597

Unrealized holding gains/(losses) on available-for-sale securities

35

(74

127

(94

Reclassification adjustments for realized (gains)/losses(a)

(9

23

24

32

26

(51

151

(62

Benefit plans: Actuarial gains/(losses)

(88

(592

Reclassification adjustments related to amortization(b)

121

68

351

208

Reclassification adjustments related to curtailments and settlements, net(b)

48

85

160

258

Other

(36

(20

18

(164

45

134

(63

306

Benefit plans: Prior service credits/(costs) and other

(3

23

Reclassification adjustments related to amortization(b)

(19

(17

(53

(52

Reclassification adjustments related to curtailments and settlements, net(b)

(4

(16

(86

(49

Other

(4

(22

(33

(116

(104

Other comprehensive income/(loss), before tax

427

(478

(1,471

1,952

Tax provision/(benefit) on other comprehensive income/(loss)(c)

73

(216

72

(276

Other comprehensive income/(loss) before allocation to noncontrolling interests

354

(262

(1,543

2,228

Comprehensive Income

Comprehensive income before allocation to noncontrolling interests

3,568

3,487

6,734

10,829

Less: Comprehensive income attributable to noncontrolling interests

35

Comprehensive income attributable to Pfizer Inc.

3,563

3,480

6,731

10,794

(a)

Reclassified into Other deductions net in the condensed consolidated statements of income.

(b)

Generally reclassified into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate in the condensed consolidated statements of income.

(c)

See Note 5B. Tax Matters: Taxes on Items of Other Comprehensive Income/(Loss).

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

September 30,

2012

December 31,

2011

(Unaudited)

Assets

Cash and cash equivalents

4,506

3,182

Short-term investments

18,462

23,270

Accounts receivable, less allowance for doubtful accounts

12,523

13,058

Inventories

7,516

6,610

Taxes and other current assets

8,849

9,380

Assets of discontinued operations and other assets held for sale

5,271

5,317

Total current assets

57,127

60,817

Long-term investments

13,429

9,814

Property, plant and equipment, less accumulated depreciation

14,606

15,921

Goodwill

44,370

44,569

Identifiable intangible assets, less accumulated amortization

47,209

51,184

Taxes and other noncurrent assets

5,862

5,697

Total assets

182,603

188,002

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt

7,774

4,016

Accounts payable

2,967

3,678

Dividends payable

1,796

Income taxes payable

1,788

1,009

Accrued compensation and related items

1,736

2,120

Other current liabilities

13,455

15,066

Liabilities of discontinued operations

1,410

1,224

Total current liabilities

29,131

28,909

Long-term debt

31,083

34,926

Pension benefit obligations

6,560

6,341

Postretirement benefit obligations

3,309

3,344

Noncurrent deferred tax liabilities

19,133

18,861

Other taxes payable

6,011

6,886

Other noncurrent liabilities

5,261

6,114

Total liabilities

100,488

105,381

Commitments and Contingencies

Preferred stock

41

45

Common stock

447

445

Additional paid-in capital

72,317

71,423

Employee benefit trusts

(2

(3

Treasury stock

(36,703

(31,801

Retained earnings

51,256

46,210

Accumulated other comprehensive loss

(5,653

(4,129

Total Pfizer Inc. shareholders equity

81,703

82,190

Equity attributable to noncontrolling interests

412

431

Total equity

82,115

82,621

Total liabilities and equity

182,603

188,002

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine Months Ended

(MILLIONS OF DOLLARS)

September 30,

2012

October 2,

2011

Operating Activities

Net income before allocation to noncontrolling interests

8,277

8,601

Adjustments to reconcile net income before allocation to noncontrolling interests to net

cash provided by operating activities:

Depreciation and amortization

5,716

6,568

Share-based compensation expense

362

347

Asset write-offs and impairment charges

865

773

Gain on sale of discontinued operations

(1,683

Deferred taxes from continuing operations

97

693

Other deferred taxes

23

145

Benefit plan contributions (in excess of)/less than expense

86

(270

Other non-cash adjustments, net

(118

(93

Other changes in assets and liabilities, net of acquisitions and divestitures

(3,510

(102

Net cash provided by operating activities

11,798

14,979

Investing Activities

Purchases of property, plant and equipment

(833

(1,062

Purchases of short-term investments

(14,587

(13,457

Proceeds from redemptions and sales of short-term investments

19,377

7,221

Net proceeds from redemptions and sales of short-term investments with

original maturities of 90 days or less

1,483

10,648

Purchases of long-term investments

(8,694

(3,646

Proceeds from redemptions and sales of long-term investments

3,357

2,001

Acquisitions, net of cash acquired

(782

(3,188

Proceeds from sale of business

2,376

Other investing activities

(4

408

Net cash provided by/(used in) investing activities

(683

1,301

Financing Activities

Proceeds from short-term borrowings

5,700

9,613

Principal payments on short-term borrowings

(3

(3,826

Net payments on short-term borrowings with original maturities of 90 days or less

(6,055

(6,243

Principal payments on long-term debt

(14

(3,486

Purchases of common stock

(4,834

(5,789

Cash dividends paid

(4,915

(4,710

Other financing activities

355

84

Net cash used in financing activities

(9,766

(14,357

Effect of exchange-rate changes on cash and cash equivalents

(25

48

Net increase in cash and cash equivalents

1,324

1,971

Cash and cash equivalents, beginning

3,182

1,735

Cash and cash equivalents, end

4,506

3,706

Supplemental Cash Flow Information

Cash paid during the period for:

Income taxes

1,895

1,539

Interest

1,675

1,872

See Notes to Condensed Consolidated Financial Statements

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.

Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and nine months ended August 26, 2012, and August 28, 2011. We have made certain reclassification adjustments to conform prior-period amounts to the current presentation, primarily related to certain inventories (see Note 8. Inventories) and the reclassification of certain investments (see Note 7. Financial Instruments).

On August 13, 2012, we filed a registration statement with the SEC for the potential initial public offering (IPO) of up to a 20% ownership stake in our Animal Health business, Zoetis Inc. (Zoetis).

On April 23, 2012, we announced that we entered into an agreement to sell our Nutrition business to Nestl . As a result, beginning in the second quarter of 2012, we report the operating results of the Nutrition business as Discontinued operations net of tax in the condensed consolidated statements of income for all periods presented. In addition, the assets and liabilities associated with this business are reported as Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the condensed consolidated balance sheets (see Note 2B. Acquisitions and Divestitures: Divestitures).

On August 1, 2011, we completed the sale of our Capsugel business. The operating results and the gain on the sale of this business are reported as Discontinued operations net of tax in the condensed consolidated statements of income for the three and nine months ended October 2, 2011 (see Note 2B. Acquisitions and Divestitures: Divestitures).

On January 31, 2011, we acquired King Pharmaceuticals, Inc. (King) and in accordance with our domestic and international reporting periods, our condensed consolidated financial statements for the nine months ended October 2, 2011 reflect approximately eight months of King s U.S. operations and approximately seven months of King s international operations (for additional information, see Note 2A. Acquisitions and Divestitures: Acquisitions).

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and results of operations.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2011 Annual Report on Form 10-K.

B. Adoption of New Accounting Standards

The provisions of the following new accounting and disclosure standards were adopted as of January 1, 2012:

Presentation of comprehensive income in financial statements. As a result of adopting this new standard, we have presented separate Condensed Consolidated Statements of Comprehensive Income.

An amendment to the guidelines on the measurement and disclosure of fair value that is consistent between U.S. GAAP and International Financial Reporting Standards. The adoption of this new standard did not have a significant impact on our financial statements.

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

C. Fair Value

Our fair value methodologies depend on the following types of inputs:

Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).

Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

Note 2. Acquisitions and Divestitures

A. Acquisitions

Nexium Over-the-Counter Rights

On August 13, 2012, we announced that we entered into an agreement with AstraZeneca for the over-the-counter (OTC) rights for Nexium, a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease. Under the terms of the agreement, we acquired the exclusive global rights to market Nexium for the approved OTC indications. We made an upfront payment of $250 million to AstraZeneca, and AstraZeneca is eligible to receive milestone payments of up to $550 million based on product launches and level of sales as well as royalty payments based on sales. The upfront payment was expensed and included in Research and development expenses in our condensed consolidated statements of income. A marketing authorization application for OTC Nexium in a 20 mg tablet form was filed with the European Medicines Agency in June 2012. A new drug application filing for OTC Nexium in the U.S. in a 20 mg delayed-release capsule is targeted for the first half of 2013.

Alacer Corp.

On February 26, 2012, we completed our acquisition of Alacer Corp., a privately owned company that manufactures, markets and distributes Emergen-C, a line of effervescent, powdered drink mix vitamin supplements that is the largest-selling branded vitamin C line in the U.S. In connection with this consumer healthcare acquisition, we recorded $247 million in Identifiable intangible assets, consisting primarily of the Emergen-C indefinite-lived brand, $94 million in net deferred tax liabilities and $151 million in Goodwill. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has been finalized.

Ferrosan Holding A/S

On December 1, 2011, we completed our acquisition of the consumer healthcare business of Ferrosan Holding A/S (Ferrosan), a Danish company engaged in the sale of science-based consumer healthcare products, including dietary supplements and lifestyle products, primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. Due to the fact that financial information included in our fiscal year 2011 consolidated financial statements for our subsidiaries operating outside the U.S. is as of and for the year ended November 30, this acquisition is reflected in our condensed consolidated financial statements beginning in the first fiscal quarter of 2012. Our acquisition of Ferrosan s consumer healthcare business increases our presence in dietary supplements with a new set of brands and pipeline products. Also, we believe that the acquisition allows us to expand the marketing of Ferrosan s brands through Pfizer s global footprint and provide greater distribution and scale for certain Pfizer brands, such as Centrum and Caltrate, in Ferrosan s key markets. In connection with this acquisition, we recorded $463 million in Identifiable intangible assets, consisting of indefinite-lived and finite-lived brands, $119 million in net deferred tax liabilities and $246 million in Goodwill. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not been finalized.

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

King Pharmaceuticals, Inc.

On January 31, 2011 (the acquisition date), we completed a tender offer for the outstanding shares of common stock of King at a purchase price of $14.25 per share in cash and acquired approximately 92.5% of the outstanding shares. On February 28, 2011, we acquired all of the remaining shares of King for $14.25 per share in cash. As a result, the total fair value of consideration transferred for King was approximately $3.6 billion in cash ($3.2 billion, net of cash acquired).

King s principal businesses consist of a prescription pharmaceutical business focused on delivering new formulations of pain treatments designed to discourage common methods of misuse and abuse; the Meridian auto-injector business for emergency drug delivery, which develops and manufactures the EpiPen; an established products portfolio; and an animal health business that offers a variety of feed-additive products for a wide range of species.

The following table provides the assets acquired and liabilities assumed from King:

(MILLIONS OF DOLLARS)

Amounts

Recognized as of

Acquisition Date

(Final)

Working capital, excluding inventories

155

Inventories

340

Property, plant and equipment

412

Identifiable intangible assets, excluding in-process research and development

1,806

In-process research and development

303

Net tax accounts

(328

All other long-term assets and liabilities, net

102

Total identifiable net assets

2,790

Goodwill(a)

765

Net assets acquired/total consideration transferred

3,555

(a)

Goodwill recorded as of the acquisition date totaled $720 million for our three biopharmaceutical operating segments and $45 million for our Animal Health operating segment. (Since the acquisition of King, we have revised our operating segments. See Note 13A. Segment, Geographic and Other Revenue Information: Segment Information.)

As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $200 million, virtually all of which was expected to be collected.

Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of King includes the following:

the expected synergies and other benefits that we believed would result from combining the operations of King with the operations of Pfizer;

any intangible assets that did not qualify for separate recognition, as well as future, yet unidentified projects and products; and

the value of the going-concern element of King s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately).

Goodwill is not amortized and is not deductible for income tax purposes (see Note 9A. Goodwill and Other Intangible Assets: Goodwill for additional information).

The assets and liabilities arising from contingencies recognized as of the acquisition date are not significant to Pfizer s condensed consolidated financial statements.

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Revenues from King are included in Pfizer's condensed consolidated statements of income from the acquisition date, January 31, 2011, through Pfizer s domestic and international quarter-ends and were $938 million in the first nine months of 2011. We are not able to provide the results of operations attributable to King in the first nine months of 2011 as those operations had been substantially integrated into the larger Pfizer operation shortly after the acquisition.

If the acquisition of King had occurred on January 1, 2011, the change to Pfizer s Revenues, Income from continuing operations attributable to Pfizer Inc. common shareholders and Diluted earnings per share attributable to Pfizer Inc. common shareholders for the first nine months of 2011 would not have been significant.

B. Divestitures

On April 23, 2012, we announced that we entered into an agreement to sell our Nutrition business to Nestl for $11.85 billion in cash. The transaction is expected to close in the next few months, assuming the receipt of the required regulatory clearances and satisfaction of other closing conditions. Beginning in the second quarter of 2012, we report the operating results of the Nutrition business as Discontinued operations net of tax in the condensed consolidated statements of income for all periods presented. The transaction also includes the sale of certain prenatal multivitamins currently commercialized by the Pfizer Consumer Healthcare business unit. The operating results of this product line are also included in Discontinued operations net of tax for all periods presented. In addition, the assets and liabilities associated with the discontinued operations are classified as Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the condensed consolidated balance sheets.

On August 1, 2011, we completed the sale of our Capsugel business for approximately $2.4 billion in cash. The operating results and the gain on the sale of this business are reported as Discontinued operations net of tax in the condensed consolidated statements of income for the three and nine months ended October 2, 2011.

The following table provides the components of Discontinued operations net of tax:

Three Months Ended

Nine Months Ended

(MILLIONS OF DOLLARS)

September 30,

2012

October 2,

2011

September 30,

2012

October 2,

2011

Revenues(a)

564

699

1,665

2,068

Pre-tax income from discontinued operations

129

121

365

397

Provision for taxes on income(b)

25

25

116

94

Income from discontinued operations net of tax

104

96

249

303

Pre-tax gain on sale of discontinued operations

1,695

1,683

Provision for taxes on income(c)

367

367

Gain on sale of discontinued operations net of tax

1,328

1,316

Discontinued operations net of tax(a)

104

1,424

249

1,619

(a)

Includes the Nutrition business for all periods presented and the Capsugel business for 2011 only.

(b)

Includes deferred tax expense of $9 million and a deferred tax benefit of $10 million for the three months ended September 30, 2012 and October 2, 2011, respectively, and a deferred tax expense of $23 million and a deferred tax benefit of $17 million for the nine months ended September 30, 2012 and October 2, 2011, respectively. These deferred tax provisions include deferred income taxes related to investments in certain foreign subsidiaries resulting from our intention not to hold these subsidiaries permanently.

(c)

Includes deferred tax expense of $162 million for the three and nine months ended October 2, 2011. These deferred tax provisions include deferred taxes on certain current-year funds earned outside the U.S. that will not be permanently reinvested overseas.

10

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table provides the components of Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations:

(MILLIONS OF DOLLARS)

September 30,

2012

December 31,

2011

Accounts receivable, less allowance for doubtful accounts

523

550

Other current assets

433

419

Property, plant and equipment, less accumulated depreciation

1,046

1,118

Goodwill

492

498

Identifiable intangible assets, less accumulated amortization

2,652

2,648

Other noncurrent assets

125

84

Assets of discontinued operations and other assets held for sale

5,271

5,317

Current liabilities

554

385

Other liabilities

856

839

Liabilities of discontinued operations

1,410

1,224